Advice

in the absence of a submission from the holder of the marketing authorisation:

atezolizumab (Tecentriq®) is not recommended for use within NHSScotland.

Indication under review: In combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.

Download detailed advice357KB (PDF)

Download

Medicine details

Medicine name:
atezolizumab (Tecentriq)
SMC ID:
SMC2254
Indication:

In combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.

Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published:
09 December 2019